Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes and heart failure commonly occur together and this combination is associated with poor outcomes. The relationship is likely to be multifactorial and also may involve a specific, though ill-defined, diabetic cardiomyopathy. Glucose-lowering therapies may also be associated with an increased risk of heart failure. Data from recent large-scale clinical trials have drawn particular attention to the thiazolidinediones that appear to increase the risk of heart failure in patients with type 2 diabetes. Although pioglitazone therapy has been shown to decrease the risk of macrovascular events, the overall cardiovascular benefit needs to be addressed together with the apparent increase in heart failure risk. In this review, we provide appropriate context for assessing this balance from several perspectives. First, we consider the high underlying risk of heart failure already present in type 2 diabetes. Secondly, we highlight a potential distinction between genuine heart failure due to cardiac dysfunction and thiazolidinedione-associated oedema that may simply unmask previously undiagnosed cardiac dysfunction without itself having any direct impact on heart muscle. Most importantly, we emphasize the apparent lack of any long-term mortality consequences and a relative improvement in outcomes associated with thiazolidinedione-induced 'heart failure' and discuss the potential mechanisms underlying this apparent paradox. Finally, we review the current guidelines for thiazolidinedione use and heart failure and suggest potential future strategies for avoiding and/or minimizing this association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“On the contrary, a recent meta-analysis of clinical trials has suggested an increased risk of myocardial infarction with rosiglitazone.(21) Furthermore, an interim analysis from the ongoing Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study”
ResultDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
The Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D. (2005) · Nature Medicine · doi:10.1038/nm1278 · Cited by 608
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458 · cited 3×
“(decrease of 8%), but were increased by 6% with thiazolidinediones.(62) Interestingly, the combination of a thiazolidinedione and metformin appeared to be even more effective, with a 24% reduction in mortality.”
BackgroundInfluentialImproved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Diamant, M., Lamb, H. J., Groeneveld, Y., Endert, E. L., Smit, J. W. A., Bax, J. J., Romijn, J. A., de Roos, A., & Radder, J. K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00625-9 · Cited by 372 · cited 2×
“which is known to be reduced in type 2 diabetes and is associated with LV diastolic dysfunction in these patients.(65) Of particular note, the PCr/ATP ratio is a strong predictor of both total and cardiovascular mortality in patients with dilated cardiomyopathy.”
Background
Cited by
Diabetic cardiomyopathy: pathophysiology and clinical features
Miki, T., Yuda, S., Kouzu, H., & Miura, T. (2013) · Heart Failure Reviews · doi:10.1007/s10741-012-9313-3 · Cited by 460
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227
Mannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
“36 Conversely, SGLT2is seem to have greater effects on coronary, rather than cerebrovascular, events.”
BackgroundLi, L., Zhang, X., Wang, L., Chai, Z., Shen, X., Zhang, Z., & Liu, C. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12251 · Cited by 8
Metadata
- Authors
- Erdmann, E., & Wilcox, R. G.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-08
- Volume
- 29
- Issue
- 1
- Pages
- 12-20
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W1969533014
- Cited by
- 79
- References
- 12
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. https://app.cochat.ai/papers/10.1093/eurheartj/ehm529
- The paper
- Erdmann, E., & Wilcox, R. G. (2007). Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. European Heart Journal. https://doi.org/10.1093/eurheartj/ehm529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.